Caren Logo
Non-Alcoholic Steatohepatitis
Non-Alcoholic Steatohepatitis

Reference for building the Care Pathway:

American Association for the Study of Liver Diseases (AASLD) - EUA

It is an internationally recognized professional organization whose importance lies in its fundamental role in research, education, and the development of clinical guidelines that guide the care of patients with liver diseases, such as hepatitis, cirrhosis, and non-alcoholic fatty liver disease (NASH).

AASLD plays an essential role in improving global liver health, bringing together science, education, and best clinical practices to address challenges in the treatment of liver diseases.

Caren has adopted the "Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease" published by AASLD as a reference to structure its care line, ensuring comprehensive and effective patient monitoring.

Care Pathway for Non-Alcoholic Steatohepatitis

The Caren care line is enhanced by an intelligent system that continuously monitors patient data, enabling early detection of signs of decompensation or complications. The platform gathers information from assessment questionnaires, laboratory tests, medical consultation records, and cardiac parameters, integrating this data to generate personalized alerts for healthcare teams.
📋 Steps:
1
Risk Stratification
2
Monitoring and Follow-up
3
Complication Prevention
Points
✅ Main objectives:
  • ✔ Identify at-risk patients before progression to advanced fibrosis.
  • ✔ Classify disease severity to guide appropriate management.
  • ✔ Implement lifestyle changes and effective drug therapies.
  • ✔ Reduce progression to cirrhosis, liver failure, and liver cancer.
📌 Expected benefits:
  • ✔ Lower risk of progression to cirrhosis and hepatic decompensation.
  • ✔ Symptom control and improved overall well-being.
  • ✔ Early and continuous treatment improves clinical outcomes.
⚡Test now:
Dialog Chatbot